VERIMATRIX
5.6.2019 07:02:05 CEST | Business Wire | Press release
Verimatrix, the leader in redefining the standard for connected devices and services with an innovative combination of security and data analytics, and IPTV technology company Ocilion today announced two large Austrian operators as their latest customers. kabelplus and Salzburg AG have each selected on-premise IPTV solutions from Ocilion that are secured by Verimatrix, enabling more flexible and future-proof video delivery models.
Both operators opted independently for on-premise deployments hosted in their distinctive infrastructures, optimally suiting larger volumes of subscribers using Ocilion’s new homogenous P400 family of 4K set-top boxes (STBs), which combines innovation, design, functionality and efficiency. The advanced and adaptable technology offers the flexibility needed to support various delivery models, whether hybrid, FTTH or OTT, while the integrated Verimatrix client supports digital rights management (DRM) for IP, IP/DVB-C and OTT.
“kabelplus and Salzburg AG came to us with unique challenges and needs that will grow and evolve as consumer demands and security requirements continue to rapidly shift,” said Hans Kühberger, CEO of Ocilion. “We are very pleased to fulfil their demands for increasingly sophisticated modern and high-end IPTV services with our future-proof on-premise solution, including our new P400 family and resolve complex security requirements in partnership with Verimatrix.”
The decision for kabelplus, the largest cable network provider in Lower Austria and Burgenland, to launch its own IPTV product resulted from the need to extend its portfolio for its HFC network with extra products and services, and it came during the middle of a FTTH expansion and rollout. In need of a competitive edge to reinforce its position as a top service provider, kabelplus saw the Ocilion-Verimatrix partnership as the perfect fit to elevate its product portfolio with new premium features and bundling options.
When live-only DVB-C delivery was no longer enough to support Salzburg AG’s consumer demands, the Salzburg energy, transport and telecommunications provider turned to Ocilion and Verimatrix to set the foundation for it to be able to offer premium service enhancements and maximize upselling opportunities with long-term adaptability.
With these deployments, the Austrian operators are also laying the foundation for secure UHD ecosystems with OcilionsP400 line of STBs having officially received the Verimatrix 4.0 Ultra Security certification. This certification emphasizes their readiness to fully meet UHD security requirements, ensuring that they meet UHD content guidelines set by MovieLabs’ Specifications for Next Generation Video and Enhanced Content Protection.
“Achieving Ultra Security certification means that Ocilion’s advanced STBs are trusted to deliver premium content to kabelplus and Salzburg AG consumers at the highest quality possible and in accordance with the strongest security requirements specified by premium rights holders,” commented Verimatrix COO Steve Oetegenn. “Ultimately, the combined strengths of Ocilion and Verimatrix presents a formidable barrier against piracy in a form that can be updated readily to ensure these operators are able to keep pace with the evolving threat landscape.”
About Ocilion
Ocilion is a software company, providing individual end-to-end IPTV platforms to network providers in German-speaking Europe (Germany, Austria, Switzerland & Liechtenstein) since 2004. The white labelled IPTV platform is suited for all network topologies (HFC, FTTH, VDSL, OTT) and contains content, services, premium TV features (Replay, PVR, VoD), a full family of pre-integrated 4K set-top boxes and apps (smartphone, tablet, Apple TV, Amazon Fire TV). Operators can choose between on-premise systems (hosted in their distinctive infrastructure) and a rental option hosted by Ocilion (optimised for medium-sized carriers). Since 2009, the IPTV specialist started IPTV building solutions for hotels, hospitals, ships, corporate buildings and other projects (iptv500 product). For more information, visit www.ocilion.com .
About Inside Secure/Verimatrix
Inside Secure/Verimatrix (Euronext Paris – INSD) is redefining the standard for connected devices and services with an innovative combination of security and data analytics that maximizes revenues, protects reputations and enables growth. The company serves a range of industries and markets, including entertainment, mobile, computer networks and internet of things (IoT). The company offers easy-to-use software solutions, cloud services and silicon IP that provides unparalleled security and business intelligence. With more than 24 years of experience and a solid reputation, Inside Secure/Verimatrix protects customers’ most valuable content, transactions, applications, and communications. With 18 office locations in 12 countries supporting more than 1,200 customers, the company is uniquely positioned to secure and enable the connected future. For more information, visit www.insidesecure.com and www.verimatrix.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604006167/en/
Contact:
Kelly Foster, Verimatrix +1 619 224 1261 kfoster@verimatrix.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom